An overview about galectin-3 and its relationship with cardiovascular diseases

Authors

Keywords:

Atherosclerosis, Galectin-3, İnflammation, Heart failure, Coronary artery disease

Abstract

Inflammation is one of the cornerstones of atherosclerosis. Galectin-3 (Gal-3) acts on the stages of the inflammatory process. Gal-3 is a candidate for being a valuable marker for heart failure (HF) and coronary artery disease (CAD). Further studies are needed for the diagnosis and follow-up of CAD. In the literature, the relationship between Gal-3 and CAD has not been researched sufficiently. We aimed to write a review by referring to recent studies about Gal-3 in the etiopathogenesis of CAD, its prognostic significance, and its contribution to the treatment regimen.

Downloads

Download data is not yet available.

References

Askin L, Tanrıverdi O. An Overview of Clinical Studies on Endocan and Cardiovascular Disease. Erciyes Med J. 2021;43(3):233-6. doi: 10.14744/etd.2020.09699.

Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galectin-3 in Cardiovascular Diseases. Int J Mol Sci. 2020;21(23):9232. doi: 10.3390/ijms21239232.

Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M, et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2015;35(3):725-32. doi: 10.1161/ATVBAHA.114.304964.

Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230(1):160-71. doi: 10.1111/j.1600-065X.2009.00794.x.

Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121-8. doi: 10.1161/01.CIR.0000147181.65298.4D.

Kusaka H, Yamamoto E, Hirata Y, Fujisue K, Tokitsu T, Sugamura K, et al. Clinical significance of plasma galectin-3 in patients with coronary artery disease. Int J Cardiol. 2015;201:532-4. doi: 10.1016/j.ijcard.2015.08.099.

Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol. 2015;182:168-70. doi: 10.1016/j.ijcard.2014.12.137.

Reifenberg K, Lehr HA, Torzewski M, Steige G, Wiese E, Küpper I, et al. Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol. 2007;171(2):463-72. doi: 10.2353/ajpath.2007.060906.

Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6(1):107-17. doi: 10.1161/CIRCHEARTFAILURE.112.971168.

Lepojärvi ES, Piira OP, Pääkkö E, Lammentausta E, Risteli J, Miettinen JA, et al. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front Physiol. 2015;6:200. doi: 10.3389/fphys.2015.00200.

McCullough PA. Practical experience using galectin-3 in heart failure. Clin Chem Lab Med. 2014;52(10):1425-31. doi: 10.1515/cclm-2014-0278.

Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J. 2014;167(6):853-60.e4. doi: 10.1016/j.ahj.2014.02.011.

Hashmi S, Al-Salam S. Galectin-3 is expressed in the myocardium very early post-myocardial infarction. Cardiovasc Pathol. 2015;24(4):213-23. doi: 10.1016/j.carpath.2014.12.001.

Coromilas E, Que-Xu EC, Moore D, Kato TS, Wu C, Ji R, et al. Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation. BMC Cardiovasc Disord. 2016;16:138. doi: 10.1186/s12872-016-0298-z.

Rieth AJ, Jung C, Gall H, Rolf A, Mitrovic V, Hamm CW, et al. Association of galectin-3 with changes in left ventricular function in recent-onset dilated cardiomyopathy. Biomarkers. 2019;24(7):652-658. doi: 10.1080/1354750X.2019.1642959.

Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60(14):1249-56. doi: 10.1016/j.jacc.2012.04.053.

Liu YH, D'Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 2009;296(2):H404-12. doi: 10.1152/ajpheart.00747.2008.

Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33(1):67-75. doi: 10.1161/ATVBAHA.112.300569.

Lax A, Sanchez-Mas J, Asensio-Lopez MC, Fernandez-Del Palacio MJ, Caballero L, Garrido IP, et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Fail. 2015;3(1):50-58. doi: 10.1016/j.jchf.2014.07.015.

Yakar Tülüce S, Tülüce K, Çil Z, Emren SV, Akyıldız Zİ, Ergene O. Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function. Anatol J Cardiol. 2016;16(5):344-8. doi: 10.5152/AnatolJCardiol.2015.6191.

de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail. 2013;15(10):1095-101. doi: 10.1093/eurjhf/hft077.

Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, Menini S. Galectin-3 in diabetic patients. Clin Chem Lab Med. 2014;52(10):1413-23. doi: 10.1515/cclm-2014-0187.

Seferovic JP, Lalic NM, Floridi F, Tesic M, Seferovic PM, Giga V, et al. Structural myocardial alterations in diabetes and hypertension: the role of galectin-3. Clin Chem Lab Med. 2014;52(10):1499-505. doi: 10.1515/cclm-2014-0265.

Tan KCB, Cheung CL, Lee ACH, Lam JKY, Wong Y, Shiu SWM. Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus. Diabetologia. 2018;61(5):1212-1219. doi: 10.1007/s00125-018-4552-z.

Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab. 2010;95(3):1404-11. doi: 10.1210/jc.2009-1619

Li P, Liu S, Lu M, Bandyopadhyay G, Oh D, Imamura T, et al. Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance. Cell. 2016;167(4):973-984.e12. doi: 10.1016/j.cell.2016.10.025.

Johnson AMF, Hou S, Li P. Inflammation and insulin resistance: New targets encourage new thinking: Galectin-3 and LTB4 are pro-inflammatory molecules that can be targeted to restore insulin sensitivity. Bioessays. 2017;39(9):10.1002/bies.201700036. doi: 10.1002/bies.201700036.

Pang J, Rhodes DH, Pini M, Akasheh RT, Castellanos KJ, Cabay RJ, et al. Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. PLoS One. 2013;8(2):e57915. doi: 10.1371/journal.pone.0057915.

Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol. 2009;29(6):831-6. doi: 10.1161/ATVBAHA.109.186791.

Tsai TH, Sung PH, Chang LT, Sun CK, Yeh KH, Chung SY, et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb. 2012;19(12):1073-82. doi: 10.5551/jat.12856.

Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J. 2012;164(6):878-83. doi: 10.1016/j.ahj.2012.08.021.

Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol. 2011;24(4):905-13. doi: 10.1177/039463201102400409.

Menini S, Iacobini C, Ricci C, Blasetti Fantauzzi C, Salvi L, Pesce CM, et al. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res. 2013;100(3):472-80. doi: 10.1093/cvr/cvt206.

Mayr A, Klug G, Mair J, Streil K, Harrasser B, Feistritzer HJ, et al. Galectin-3: relation to infarct scar and left ventricular function after myocardial infarction. Int J Cardiol. 2013;163(3):335-337. doi: 10.1016/j.ijcard.2012.06.087.

Gao Z, Liu Z, Wang R, Zheng Y, Li H, Yang L. Galectin-3 Is a Potential Mediator for Atherosclerosis. J Immunol Res. 2020;2020:5284728. doi: 10.1155/2020/5284728.

Winter MP, Wiesbauer F, Alimohammadi A, Blessberger H, Pavo N, Schillinger M, et al. Soluble galectin-3 is associated with premature myocardial infarction. Eur J Clin Invest. 2016;46(5):386-91. doi: 10.1111/eci.12605.

Aksan G, Gedikli Ö, Keskin K, Nar G, İnci S, Yıldız SS, et al. Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis? J Investig Med. 2016;64(3):764-70. doi: 10.1136/jim-2015-000041.

Gleissner CA, Erbel C, Linden F, Domschke G, Akhavanpoor M, Doesch AO, et al. Galectin-3 binding protein plasma levels are associated with long-term mortality in coronary artery disease independent of plaque morphology. Atherosclerosis. 2016;251:94-100. doi: 10.1016/j.atherosclerosis.2016.06.002.

Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J. 2014;167(5):729-34.e1. doi: 10.1016/j.ahj.2014.02.009.

Sonmez O, Ertem FU, Vatankulu MA, Erdogan E, Tasal A, Kucukbuzcu S, et al. Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation. Med Sci Monit. 2014;20:463-70. doi: 10.12659/MSM.890635.

Gurses KM, Yalcin MU, Kocyigit D, Canpinar H, Evranos B, Yorgun H, et al. Effects of persistent atrial fibrillation on serum galectin-3 levels. Am J Cardiol. 2015;115(5):647-51. doi: 10.1016/j.amjcard.2014.12.021.

Kocyigit D, Gurses KM, Yalcin MU, Canpinar H, Canpolat U, Evranos B, et al. Serum galectin-3 level as a marker of thrombogenicity in atrial fibrillation. J Clin Lab Anal. 2017;31(6):22120. doi: 10.1002/jcla.22120.

Clementy N, Benhenda N, Piver E, Pierre B, Bernard A, Fauchier L, et al. Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation. Sci Rep. 2016;6:34357. doi: 10.1038/srep34357.

Clementy N, Piver E, Bisson A, Andre C, Bernard A, Pierre B, et al. Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications. Int J Mol Sci. 2018;19(4):976. doi: 10.3390/ijms19040976.

Numano F, Shimizu C, Jimenez-Fernandez S, Vejar M, Oharaseki T, Takahashi K, et al. Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms. Int J Cardiol. 2015;201:429-37. doi: 10.1016/j.ijcard.2015.07.063.

Downloads

Published

2021-12-01

How to Cite

1.
Aşkın L, Aşkın H, Tanrıverdi O, Özyıldız AG, Hidayet Şıho. An overview about galectin-3 and its relationship with cardiovascular diseases. J Surg Med [Internet]. 2021 Dec. 1 [cited 2022 Nov. 28];5(12):1218-20. Available from: https://jsurgmed.com/article/view/933280